中文摘要：

目的比较紫杉醇联合替吉奥与紫杉醇联合卡培他滨治疗晚期食管癌的近期临床疗效及不良反应。方法 47例晚期食管癌患者入组,25例接受紫杉醇联合替吉奥方案化疗,22例接受紫杉醇联合卡培他滨方案化疗,每3周为1个周期,至少完成2个周期,比较二组患者的近期有效率和不良反应。结果紫杉醇联合替吉奥组和紫杉醇联合卡培他滨组的近期有效率分别为52.0%和40.9%（P=0.447）,二组差异无统计学意义。常见的不良反应为粒细胞减少、手足综合征及脱发等。紫杉醇联合卡培他滨组手足综合征发生率高于紫杉醇联合替吉奥组（P=0.042）,但均可耐受。结论紫杉醇联合替吉奥和紫杉醇联合卡培他滨方案治疗晚期食管癌疗效相当,不良反应可以耐受,值得临床推广。

英文摘要：

Objective To compare the clinical efficacy and adverse reaction of Paclitaxel and S- 1 and Paclitaxel and Capecitabine in the treatment of advanced esophageal cancer. Methods Totally 47 cases of advanced esophageal cancer were selected as subjects, group A of 25 patients received Paclitaxel and S- 1 chemotherapy, group B of 22 patients received Paclitaxel and Capecitabine chemotherapy, every 3 weeks for a cycle, at least 2 cycles, compared two groups of patients with recent effective rate and adverse reaction. Results The recent effective rate were 52% and 40.9% in group A and group B, there was no significant difference between the two groups（P = 0. 447）. Common adverse reactions in both groups were neutropenia, hand foot syndrome and alopecia. The hand foot syndrome incidence of group A was lower than group B （P = 0. 042）, but which can tolerate. Conclusion The recent effective rate of Paclitaxel and S- 1 and Paelitaxel and Capeeitabine in treatment of advanced esophageal cancer are quite, tolerability, is worth the clinical promotion.